Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Bibliographic Details
Main Authors:	Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Patrick Lefebvre, Steven R. Feldman
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-09-01
Series:	Dermatology and Therapy
Subjects:	Biologics Guselkumab Persistence Psoriasis Remission Treatment discontinuation
Online Access:	https://doi.org/10.1007/s13555-023-01017-8

Internet